MediWound Ltd.

MediWound Ltd. is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration. The company focuses on next-generation enzymatic therapeutics with a mission to enhance existing standards of care, improve patient experiences, and reduce costs and unnecessary surgeries. Its headquarters are located in Yavne, Israel.

MediWound's primary commercial product is NexoBrid, an FDA-approved orphan biologic designed for the enzymatic removal of eschar in deep partial- and full-thickness thermal burns. NexoBrid is marketed in the U.S., European Union, Japan, and other international markets. The company also has a robust pipeline, including EscharEx, a late-stage investigational therapy for the debridement of chronic and hard-to-heal wounds such as venous leg ulcers and diabetic foot ulcers. Additionally, MW005 is a topically applied biological candidate in development for the treatment of non-melanoma skin cancers.

Ofer Gonen serves as the Chief Executive Officer, having been appointed in June 2022. In recent developments, MediWound's expanded NexoBrid manufacturing facility became operational in early 2026, aiming to increase production capacity sixfold, with regulatory approvals anticipated later in the year. The company's EscharEx Phase III VALUE trial for venous leg ulcers is progressing, with key milestones expected by year-end 2026, and plans for expansion into diabetic foot ulcers and pressure ulcers in the second half of 2026. MediWound reported $17 million in revenue for 2025 and reaffirmed its revenue guidance for 2026-2028. The company also announced a BARDA contract award to Vericel for NexoBrid, valued at up to $197 million, in April 2026. Strategic partnerships with companies like Coloplast, Convatec, Essity, Mölnlycke, Solventum, and MiMedx support the EscharEx program.